Therefore, the current research aimed to test the hypothesis that SIK1 plays an antineoplastic role by inhibiting the activation of the TGF-β signaling pathway and then inhibiting EMT and oxaliplatin resistance, accordingly providing a different therapeutic target for CRC. The gene discussed is TGFB1; the disease is colorectal carcinoma.